Physician profile
Erin Cooley
NPI 1730671538
$2,820.11
in general payments reported to CMS, 2019-2025
23 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $507 · 2023: $746 · 2024: $859 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,134.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $732.76 | 2022-2025 | |
| Lilly USA, LLC | $433.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $369.29 | 2022-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $256.00 | 2021-2025 | Farxiga, Breztri |
| Pfizer INC. | $146.45 | 2023-2025 | |
| Intuitive Surgical, INC. | $143.88 | 2023 | Da Vinci Surgical System |
| Bayer Healthcare Pharmaceuticals INC. | $127.13 | 2022-2025 | |
| Glaxosmithkline, LLC. | $86.25 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $70.34 | 2021-2024 | Injectafer |
| Novo Nordisk INC | $66.71 | 2021-2024 | Rybelsus, Wegovy |
| Lundbeck LLC | $55.03 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $50.81 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $41.00 | 2025 | Korlym |
| Shield Therapeutics INC | $36.84 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $34.54 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.85 | 2022 | |
| Merck Sharp & Dohme LLC | $27.81 | 2023 | Dificid |
| Medtronic, INC. | $24.09 | 2022 | |
| Averitas Pharma INC. | $19.91 | 2025 | Qutenza |
| Abbott Laboratories | $19.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.36 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $16.80 | 2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.